Erratum: Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2 (Journal of Clinical Investigation (2011) 121, 4 (1412-1423) DOI:10.1172/JCI42894);Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocytespecific deletion of JAK2

Journal of Clinical Investigation

Volumn 121, Issue 4, 2011, Pages 1412-1423

  Sos, Brandon C ^a   Harris, Charles ^a,b   Nordstrom, Sarah M ^a   Tran, Jennifer L ^a   Balázs, Mercedesz ^c   Caplazi, Patrick ^d   Febbraio, Maria ^e   Applegate, Milana A B ^e   Wagner, Kay Uwe ^f   Weiss, Ethan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^c Gladstone Institute of Cardiovascular Diseases ^*  (United States)

^d GENENTECH INC   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CD36 ANTIGEN; GROWTH HORMONE; JANUS KINASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BODY FAT; CONTROLLED STUDY; FATTY LIVER; FEMALE; GROWTH HORMONE RELEASE; LIPOLYSIS; LIVER CELL; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 79953301147     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI59854     Document Type: Erratum

References (75)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-1231.
2. Choi CS, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem. 2007;282(31):22678-22688.
3. Choi CS, et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci U S A. 2007;104(42):16480-16485.
4. Michael MD, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Molecular Cell. 2000; 6(1):87-97.
5. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000; 6(9):998-1003.
6. Dentin R, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob Mice. Diabetes. 2006;55(8):2159-2170. (Pubitemid 44743612)
7. Lee Y, et al. Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem. 2001;276(8):5629-5635.
8. Cai D, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11(2):183-190. (Pubitemid 40321354)
9. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343(20):1467-1476.
10. Feingold KR, Grunfeld C. Tumor necrosis factoralpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest. 1987;80(1):184-190. (Pubitemid 17097532)
11. Endo M, Masaki T, Seike M, Yoshimatsu H. TNFalpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med (Maywood). 2007;232(5):614-621. (Pubitemid 46683386)
12. Cressman DE, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274(5291):1379-1383. (Pubitemid 26391463)
13. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis. 1999;19(2):205-219.
14. Cui Y, et al. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology. 2007;46(2):504-513. (Pubitemid 47344786)
15. Ueki K, Kadowaki T, Kahn CR. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res. 2005;33(2):185-192. (Pubitemid 41799802)
16. Ueki K, Kondo T, Tseng Y-H, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A. 2004;101(28):10422- 10427. (Pubitemid 38924941)
17. Jansson JO, Eden S, Isaksson O. Sexual dimorphism in the control of growth hormone secretion. Endocr Rev. 1985;6(2):128-150.
18. Isaksson OG, Eden S, Jansson JO. Mode of action of pituitary growth hormone on target cells. Annu Rev Physiol. 1985;47:483-499. (Pubitemid 15142393)
19. Souza SC, Frick GP, Wang X, Kopchick JJ, Lobo RB, Goodman HM. A single arginine residue deter mines species specificity of the human growth hormone receptor. Proc Natl Acad Sci U S A. 1995;92(4):959-963.
20. Lanning N, Carter-Su C. Recent advances in growth hormone signaling. Rev Endocr Metab Disord. 2006;7(4):225-235. (Pubitemid 46399314)
21. Levy DE, Darnell JE. STATs: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651-662. (Pubitemid 34987786)
22. Rowland JE, et al. In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol Cell Biol. 2005;25(1):66-77.
23. Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan DR. STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology. 2001;142(9):3836-3841. (Pubitemid 32802654)
24. Zhou Y, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci U S A. 1997; 94(24):13215-13220. (Pubitemid 27518502)
25. Teglund S, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93(5):841-850. (Pubitemid 28257589)
26. Holloway MG, Cui Y, Laz EV, Hosui A, Hennighausen L, Waxman DJ. Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. Endocrinology. 2007; 148(5):1977-1986. (Pubitemid 46997034)
27. Wallenius K, et al. Liver-derived IGF-I regulates GH secretion at the pituitary level in mice. Endocrinology. 2001;142(11):4762-4770. (Pubitemid 33022351)
28. Sjogren K, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A. 1999;96(12):7088-7092. (Pubitemid 29275014)
29. Yakar S, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest. 2004;113(1):96-105. (Pubitemid 38541636)
30. Fan Y, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem. 2009;284(30):19937-19944.
31. Braun T, Fábry P, Petrásek R. Influence of previous feeding with a high-fat diet on liver steatosis produced by acute starvation or growth hormone in mice. Experientia. 1963;19:47-48.
32. Takahashi Y, et al. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology. 2007; 132(3):938-943. (Pubitemid 46454267)
33. Orian JM, Seong Lee C, Weiss LM, Brandon MR. The expression of a metallothionein-ovine growth hormone fusion gene in transgenic mice does not impair fertility but results in pathological lesions in the liver. Endocrinology. 1989;124(1):455-463. (Pubitemid 19033681)
34. Greenhalgh CJ, et al. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest. 2005;115(2):397-406. (Pubitemid 40385481)
35. Metcalf D. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 2000; 405(6790):1069-1073. (Pubitemid 30447793)
36. Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, Rosenfeld MG. Molecular basis of the little mouse phenotype and implications for cell typespecific growth. Nature. 1993;364(6434):208-213. (Pubitemid 23257078)
37. Eicher EM, Beamer WG. Inherited ateliotic dwarfism in mice. Characteristics of the mutation, little, on chromosome 6. J Hered. 1976;67(2):87-91.
38. Yamaoka K, Saharinen P, Pesu M, Holt V, Silvennoinen O, O'Shea J. The Janus kinases (Jaks). Genome Biology. 2004;5(12):253.
39. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004; 117(pt 8):1281-1283. (Pubitemid 38559804)
40. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essentialdevelopmental checkpoint in definitive hematopoiesis. Cell. 1998;93(3):397-409. (Pubitemid 28232084)
41. Parganas E, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998; 93(3):385-395. (Pubitemid 28232083)
42. Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, Wagner KU. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis. 2004;40(1):52-57. (Pubitemid 39655118)
43. Møller N, Gjedsted J, Gormsen L, Fuglsang J, Djurhuus C. Effects of growth hormone on lipid metabolism in humans. Growth Horm IGF Res. 2003; 13(suppl A):S18-S21. (Pubitemid 37161650)
44. Fain JN, Ihle JH, Bahouth SW. Stimulation of lipolysis but not of leptin release by growth hormone is abolished in adipose tissue from Stat5a and b knockout mice. Biochem Biophys Res Commun. 1999;263(1):201-205. (Pubitemid 29443663)
45. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001;7(1):48-52. (Pubitemid 32095641)
46. Zhou Y-C, Waxman DJ. STAT5b Down-regulates peroxisome proliferator-activated receptor a transcription by inhibition of ligand-independent activation function region-1trans-activation domain. J Biol Chem. 1999;274(42):29874-29882.
47. Postic C, Magnuson MA. DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis. 2000;26(2):149-150. (Pubitemid 30158104)
48. Sakharova AA, et al. Role of growth hormone in regulating lipolysis, proteolysis, and hepatic glucose production during fasting. J Clin Endocrinol Metab. 2008;93(7):2755-2759. (Pubitemid 352008547)
49. Jansson JO, Downs TR, Beamer WG, Frohman LA. Receptor-associated resistance to growth hormone-releasing factor in dwarf "little" mice. Science. 1986;232(4749):511-512.
50. Takahashi S, Satozawa N. The 20-kD human growth hormone reduces body fat by increasing lipolysis and decreasing lipoprotein lipase activity. Horm Res. 2002;58(4):157-164.
51. Nguyen P, et al. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl). 2008;92(3):272-283. (Pubitemid 351670169)
52. Cheung L, et al. Hormonal and nutritional regulation of alternative CD36 transcripts in rat liver - a role for growth hormone in alternative exon usage. BMC Mol Biol. 2007;8:60.
53. Memon RA, Fuller J, Moser AH, Smith PJ, Grunfeld C, Feingold KR. Regulation of putative fatty acid transporters and Acyl-CoA synthetase in liver and adipose tissue in ob/ob mice. Diabetes. 1999;48(1):121-127. (Pubitemid 29019362)
54. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert SW. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 2008;27(7):1017-1028. (Pubitemid 351508160)
55. Hosui A, Kimura A, Yamaji D, Zhu BM, Na R, Hennighausen L. Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation. J Exp Med. 2009; 206(4):819-831.
56. Uotani S, Abe T, Yamaguchi Y. Leptin activates AMP-activated protein kinase in hepatic cells via a JAK2-dependent pathway. Biochem Biophys Res Comm. 2006;351(1):171-175. (Pubitemid 44635422)
57. Keller U, Miles JM. Growth hormone and lipids. Horm Res. 1991;36(suppl 1):36-40.
58. Berryman DE, et al. Two-year body composition analyses of long-lived GHR null mice. J Gerontol A Biol Sci Med Sci. 2010;65(1):31-40.
59. Bartke A, Chandrashekar V, Bailey B, Zaczek D, Turyn D. Consequences of growth hormone (GH) overexpression and GH resistance. Neuropeptides. 2002;36(2-3):201-208.
60. Attie AD, et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res. 2002;43(11):1899-1907. (Pubitemid 35315808)
61. Kotronen A, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes. 2009;58(1):203-208.
62. Stahl A, Gimeno RE, Tartaglia LA, Lodish HF. Fatty acid transport proteins: a current view of a growing family. Trends Endocrinol Metab. 2001;12(6):266-273. (Pubitemid 33714217)
63. Bonen A, et al. Regulation of fatty acid transport by fatty acid translocase/CD36. Proc Nutr Soc. 2004; 63(2):245-249. (Pubitemid 38787473)
64. Ibrahimi A, et al. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem. 1999;274(38):26761-26766.
65. Zhou J, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPAR[gamma] in promoting steatosis. Gastroenterology. 2008; 134(2):556-567.e551.
66. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPAR[gamma] promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93(2):241-252. (Pubitemid 28180857)
67. Gan SK, Watts GF. Is adipose tissue lipolysis always an adaptive response to starvation? implications for non-alcoholic fatty liver disease. Clin Sci (London). 2008;114(8):543-545. (Pubitemid 351548761)
68. Postic C, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem. 1999;274(1):305-315. (Pubitemid 29035064)
69. Dolganov GM, et al. A novel method of gene transcript profiling in airway biopsy homogenates reveals increased expression of a Na+-K+-Cl-cotransporter (NKCC1) in asthmatic subjects. Genome Res. 2001;11(9):1473-1483. (Pubitemid 32894673)
70. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264(23):3007-3012.
71. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28(6):1379-1388. (Pubitemid 12125081)
72. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
73. Bederman IR, Foy S, Chandramouli V, Alexander JC, Previs SF. Triglyceride synthesis in epididymal adipose tissue: contribution of glucose and non-glucose carbon sources. J Biol Chem. 2009;284(10):6101-6108.
74. Lee WN, et al. Measurement of fractional lipid synthesis using deuterated water (2H2O) and mass isotopomer analysis. Am J Physiol. 1994; 266(3 pt 1):E372-E383. (Pubitemid 24115791)
75. Diraison F, Pachiaudi C, Beylot M. Measuring lipogenesis and cholesterol synthesis in humans with deuterated water: use of simple gas chromatographic/mass spectrometric techniques. J Mass Spectrom. 1997;32(1):81-86. (Pubitemid 27046476)